202 related articles for article (PubMed ID: 28060398)
1. Incomplete Retinal Vascularization After Ranibizumab Treatment of Retinopathy of Prematurity.
Day S; Rainey AM; Harper CA
Ophthalmic Surg Lasers Imaging Retina; 2017 Jan; 48(1):75-78. PubMed ID: 28060398
[TBL] [Abstract][Full Text] [Related]
2. The Process of Retinal Vascularization after Anti-VEGF Treatment in Retinopathy of Prematurity: A Comparison Study between Ranibizumab and Bevacizumab.
Alyamaç Sukgen E; Çömez A; Koçluk Y; Cevher S
Ophthalmologica; 2016; 236(3):139-147. PubMed ID: 27682852
[TBL] [Abstract][Full Text] [Related]
3. Nonresponse and Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Treatment.
Chuluunbat T; Chan RV; Wang NK; Lien R; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
Ophthalmic Surg Lasers Imaging Retina; 2016 Dec; 47(12):1095-1105. PubMed ID: 27977832
[TBL] [Abstract][Full Text] [Related]
4. Retinopathy of Prematurity Reactivated 28 Months after Injection of Ranibizumab.
Ji MH; Moshfeghi DM; Callaway NF; Bodnar Z; Schachar IH; Amorelli GM; Orazi L; Molle F; Lepore D
Ophthalmol Retina; 2019 Oct; 3(10):913-915. PubMed ID: 31474514
[No Abstract] [Full Text] [Related]
5. Persistent Angiographic Abnormalities After Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity.
Shah N; Gupta MP; Chan RVP
JAMA Ophthalmol; 2018 Apr; 136(4):436-437. PubMed ID: 29285531
[No Abstract] [Full Text] [Related]
6. FLUORESCEIN ANGIOGRAPHIC EVALUATION OF PERIPHERAL RETINAL VASCULATURE AFTER PRIMARY INTRAVITREAL RANIBIZUMAB FOR RETINOPATHY OF PREMATURITY.
Harper CA; Wright LM; Young RC; Read SP; Chang EY
Retina; 2019 Apr; 39(4):700-705. PubMed ID: 29300248
[TBL] [Abstract][Full Text] [Related]
7. Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab.
Tong Q; Yin H; Zhao M; Li X; Yu W
BMC Ophthalmol; 2018 Jun; 18(1):150. PubMed ID: 29940900
[TBL] [Abstract][Full Text] [Related]
8. Reactivation of Retinopathy of Prematurity Three Years After Treatment With Bevacizumab.
Hajrasouliha AR; Garcia-Gonzales JM; Shapiro MJ; Yoon H; Blair MP
Ophthalmic Surg Lasers Imaging Retina; 2017 Mar; 48(3):255-259. PubMed ID: 28297039
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children.
Kabataş EU; Kurtul BE; Altıaylık Özer P; Kabataş N
Curr Eye Res; 2017 Jul; 42(7):1054-1058. PubMed ID: 28128986
[TBL] [Abstract][Full Text] [Related]
10. Primary intravitreal ranibizumab for high-risk retinopathy of prematurity.
Baumal CR; Goldberg RA; Fein JG
Ophthalmic Surg Lasers Imaging Retina; 2015 Apr; 46(4):432-8. PubMed ID: 25970863
[TBL] [Abstract][Full Text] [Related]
11. Very Late Reactivation of Retinopathy of Prematurity After Monotherapy With Intravitreal Bevacizumab.
Snyder LL; Garcia-Gonzalez JM; Shapiro MJ; Blair MP
Ophthalmic Surg Lasers Imaging Retina; 2016 Mar; 47(3):280-3. PubMed ID: 26985803
[TBL] [Abstract][Full Text] [Related]
12. [The clinical study on intravitreous injection of ranibizumab for aggressive posterior retinopathy of prematurity].
Tian R; Zhang G; Tang S; Guo J; Tan W
Zhonghua Yan Ke Za Zhi; 2015 Nov; 51(11):822-5. PubMed ID: 26850583
[TBL] [Abstract][Full Text] [Related]
13. Aggressive Posterior Retinopathy of Prematurity Treated with Intravitreal Bevacizumab: Late Period Fluorescein Angiographic Findings.
Perente I; Eris E; Seymen Z; Cevik SG; Bekmez S
Graefes Arch Clin Exp Ophthalmol; 2019 Jun; 257(6):1141-1146. PubMed ID: 30895452
[TBL] [Abstract][Full Text] [Related]
14. Effects of Intravitreal Ranibizumab in the Treatment of Retinopathy of Prematurity in Chinese Infants.
Yi Z; Su Y; Zhou Y; Zheng H; Ye M; Xu Y; Chen C
Curr Eye Res; 2016 Aug; 41(8):1092-1097. PubMed ID: 26580816
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Bevacizumab and Ranibizumab in the Treatment of Type 1 Retinopathy of Prematurity Affecting Zone 1.
Kimyon S; Mete A
Ophthalmologica; 2018; 240(2):99-105. PubMed ID: 29920490
[TBL] [Abstract][Full Text] [Related]
16. FLUORESCEIN ANGIOGRAPHY EVALUATION OF CHILDREN PREVIOUSLY TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY FOR RETINOPATHY OF PREMATURITY.
Poslu Karademir F; Vural A; Özbaş M; Demirayak B
Retina; 2024 May; 44(5):901-908. PubMed ID: 38150651
[TBL] [Abstract][Full Text] [Related]
17. Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Monotherapy: Timing and Risk Factors.
Lyu J; Zhang Q; Chen CL; Xu Y; Ji XD; Li JK; Huang QJ; Zhao PQ
Invest Ophthalmol Vis Sci; 2017 Mar; 58(3):1719-1725. PubMed ID: 28324112
[TBL] [Abstract][Full Text] [Related]
18. A Surgical Technique for the Management of Tractional Retinal Detachment in Aggressive Posterior Retinopathy of Prematurity Treated With Intravitreal Bevacizumab.
De la Huerta I; Yonekawa Y; Thomas BJ; Capone A
Retina; 2019 Oct; 39 Suppl 1():S156-S159. PubMed ID: 30198966
[No Abstract] [Full Text] [Related]
19. Topical Squalamine 0.2% and Intravitreal Ranibizumab 0.5 mg as Combination Therapy for Macular Edema Due to Branch and Central Retinal Vein Occlusion: An Open-Label, Randomized Study.
Wroblewski JJ; Hu AY
Ophthalmic Surg Lasers Imaging Retina; 2016 Oct; 47(10):914-923. PubMed ID: 27759857
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings.
Lepore D; Quinn GE; Molle F; Baldascino A; Orazi L; Sammartino M; Purcaro V; Giannantonio C; Papacci P; Romagnoli C
Ophthalmology; 2014 Nov; 121(11):2212-9. PubMed ID: 25001158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
